BioLineRx Ltd. BLRX
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -65.20%
- 1 year
- -71.48%
5D -0.43 (-27.74%)
- Market cap
- 4.80M
- Revenue (ttm)
- 17.05M
- Profit margin
- -176.67%
- Shares out
- 84.11M
- Forward P/E
- -1.06
- YTD return
- -65.20%
- 1-year return
- -71.48%
- 50-day average
- 0.3624
- Volume
- 38.77K
- Avg volume
- 22.86K
- Open
- 1.10
- Previous close
- 1.05
- Day's range
- 0.78 – 1.10
- 52-week range
- 0.78 – 3.95
- Beta
- 0.87
- Price target
- 4.57 (+373.8%)
Key statistics
- 200-day average
- 0.62615
- Enterprise value
- 316.99M
- Price / sales
- 1.34
- Price / book
- 19.45
- Free cash flow
- -15.81M
- Total cash
- 40.06M
- Total debt
- 31.25M
- Return on equity
- -171.94%
- Short % of float
- 1.33%
Fundamental scorecard
5 of 25 checks passed on BLRX’s reported financials
5of 25 checks passed
- Value 2 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 25, 2024 | Sep 1, 2024 | -0.08 | -0.07 | +0.01 | +12.50% |
| Aug 15, 2024 | Jun 1, 2024 | -0.08 | 0.01 | +0.09 | +112.50% |
| May 28, 2024 | Mar 1, 2024 | -0.29 | -0.01 | +0.28 | +96.55% |
| Mar 26, 2024 | Dec 1, 2023 | -0.22 | -0.15 | +0.07 | +31.82% |
| Nov 20, 2023 | Sep 1, 2023 | -0.18 | -0.30 | -0.12 | -66.67% |
| Aug 30, 2023 | Jun 1, 2023 | -0.16 | -0.30 | -0.14 | -87.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- biolinerx.com
News
BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session BioLineRx Agrees To Sell Its Rights To Certain Future Royalty Payments From APHEXDA To Soleus Capital Management And Its Affiliates For One-Time Payment Of $5.6M
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026 BioLineRx And Hemispherian Present Two Posters Featuring GLIX1 At 31st Society For Neuro-Oncology Annual Meeting
BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026 BioLineRx And Hemispherian Present Data At ESMO 2026 Demonstrating Synergy Between GLIX1 And Multiple PARPi In Homologous Recombination-Proficient Ovarian Cancer Cell Lines And In In Vivo Patient-Derived Xenograft Model
Your note
Sign in to keep a note on BLRX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alyeska Investment Group, L.p. | 1.08% | 866,495 | 202.24K | Sep 29, 2024 |
| CVI Holdings, LLC | 1.02% | 815,683 | 190.38K | Jun 29, 2024 |
| Envestnet Asset Management | 0.30% | 239,186 | 55.83K | Sep 29, 2024 |
| Values First Advisors, Inc. | 0.25% | 197,516 | 46.10K | Sep 29, 2024 |
| Morgan Stanley | 0.25% | 197,537 | 46.10K | Sep 29, 2024 |
| Atria Investments, Inc. | 0.17% | 133,974 | 31.27K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 39,993 | 9.33K | Oct 30, 2024 |
